
|Videos|August 29, 2017
Dr. du Bois on the Potential Impact of Cytoreductive Surgery in Ovarian Cancer
Author(s)Andreas du Bois, MD, PhD
Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses the potential impact of cytoreductive surgery in ovarian cancer.
Advertisement
Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses the potential impact of cytoreductive surgery in ovarian cancer.
Surgical resection in recurrent ovarian cancer could add to the prognosis and well-being of the patient, says du Bois.
There are 2 thresholds to pass though, adds du Bois—eligibility for resection and finding the right institution.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5



































